- |||||||||| Lacripep (synthetic lacritin) / TearSolutions
Journal: A synthetic tear protein resolves dry eye through promoting corneal nerve regeneration. (Pubmed Central) - Sep 10, 2022
Intriguingly, the restorative effects of Lacripep occur despite extensive immune cell infiltration, suggesting tissue reinnervation and regeneration can be achieved under chronic inflammatory conditions. In summary, our data highlight Lacripep as a first-in-class regenerative therapy for returning the cornea to a near homeostatic state in individuals who suffer from dry eye.
- |||||||||| Lacripep (synthetic lacritin) / TearSolutions
[VIRTUAL] LacripepTM-like Peptide N-104 Increases Insulin Secretion and Promotes Islet Transplantation Outcomes () - May 18, 2021 - Abstract #ATC2021ATC_1267;
Building on years of bench, preclinical and now first-in-human studies, we propose topical lacritin peptide 'N-94 or N-94/C-6 (Lacripep)' as a novel regenerative, natural replacement therapy approach for dry eye. Islet viability, glucose stimulated insulin secretion, and transplantation outcomes indicate that N-104 is the most viable candidate for clinical translation as an interventional agent to promote islet transplantation outcomes.
- |||||||||| Lacripep (synthetic lacritin) / TearSolutions
[VIRTUAL] LacripepTM-like Peptide N-104 Promotes Beta Cell Proliferation in Murine Pancreatic Islets () - May 18, 2021 - Abstract #ATC2021ATC_1160;
Islet viability, glucose stimulated insulin secretion, and transplantation outcomes indicate that N-104 is the most viable candidate for clinical translation as an interventional agent to promote islet transplantation outcomes. Our data indicate that systemic N-104 treatment promoted single cell proliferation in islets, especially that of beta cells, without affecting exocrine acinar cell proliferation.
- |||||||||| Lacripep (synthetic lacritin) / TearSolutions
Journal: Biosynthesized Multivalent Lacritin Peptides Stimulate Exosome Production in Human Corneal Epithelium. (Pubmed Central) - Feb 23, 2021
However, cells at low density treated with 1 μM LP-A96 generated a 210-fold higher number of exosomes compared to those treated at low density with Lacripep. As monovalent Lacripep is capable of enhancing cell motility but not exosome biogenesis, activation of exosome biogenesis by LP-A96 not only suggests its utility as a novel molecular tool to study the Lacritin biology in the corneal epithelium but also implies activity as a potential therapeutic peptide that can further improve ocular surface health through the induction of exosomes.
- |||||||||| Lacripep (synthetic lacritin) / TearSolutions
[VIRTUAL] LacripepTM and its Analogs Act as Novel Interventional Agents to Promote Long-Term Islet Transplantation Outcomes (Virtual) - May 29, 2020 - Abstract #ATC2020ATC_1167;
P1/2
As monovalent Lacripep is capable of enhancing cell motility but not exosome biogenesis, activation of exosome biogenesis by LP-A96 not only suggests its utility as a novel molecular tool to study the Lacritin biology in the corneal epithelium but also implies activity as a potential therapeutic peptide that can further improve ocular surface health through the induction of exosomes. Lacripep™ and its analogs represent a novel class of interventional agents that can significantly enhance islet viability, increase insulin secretion, and promote long term longitudinal graft survival, indicating their immense potential for promoting clinical islet transplantation outcomes.
- |||||||||| Lacripep (synthetic lacritin) / TearSolutions
Trial completion: Lacripep (clinicaltrials.gov) - Jan 21, 2020
P1/2, N=204, Completed,
Lacripep™ and its analogs represent a novel class of interventional agents that can significantly enhance islet viability, increase insulin secretion, and promote long term longitudinal graft survival, indicating their immense potential for promoting clinical islet transplantation outcomes. Active, not recruiting --> Completed
- |||||||||| Lacripep (synthetic lacritin) / TearSolutions
Enrollment closed: Lacripep (clinicaltrials.gov) - Nov 15, 2019
P1/2, N=201, Active, not recruiting,
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| Lacripep (synthetic lacritin) / TearSolutions
Trial completion date, Trial primary completion date: Lacripep (clinicaltrials.gov) - Jul 29, 2019
P1/2, N=201, Recruiting,
Recruiting --> Active, not recruiting Trial completion date: Jun 2019 --> Sep 2019 | Trial primary completion date: Jun 2019 --> Sep 2019
- |||||||||| Lacripep (synthetic lacritin) / TearSolutions
Trial completion date, Trial primary completion date: Lacripep (clinicaltrials.gov) - Aug 9, 2018
P1/2, N=201, Recruiting,
Trial completion date: Jun 2019 --> Sep 2019 | Trial primary completion date: Jun 2019 --> Sep 2019 Trial completion date: Jun 2018 --> Jun 2019 | Trial primary completion date: Jun 2018 --> Jun 2019
- |||||||||| Lacripep (synthetic lacritin) / TearSolutions
New P1/2 trial: Lacripep (clinicaltrials.gov) - Jul 20, 2017
P1/2, N=201, Recruiting,
|
